Benjamin L. Schlechter, MD, discusses safety with botensilimab plus balstilimab in MSS CRC.
Benjamin L. Schlechter, MD
Advertisement
Instructor, Medicine, Harvard Medical School and an attending Physician, Medical Oncology, Dana-Farber Cancer Institute.
Articles by Benjamin L. Schlechter, MD
Benjamin L. Schlecter, MD, discusses the potential next steps in research for botensilimab for the treatment of patients with metastatic colorectal cancer.
Benjamin L. Schlechter, MD, discusses efficayc and safety of botensilimab in combination with the anti–PD-1 antibody balstilimab in mCRC.
Benjamin L. Schlechter, MD, discusses the future implications of TAC01-HER2 therapy in patients with HER2-positive solid tumors.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5